Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr5.45 SEK
Change Today +0.10 / 1.87%
Volume 75.7K
KAN On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
As of 4:27 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

kancera ab (KAN) Snapshot

Open
kr5.35
Previous Close
kr5.35
Day High
kr5.50
Day Low
kr5.25
52 Week High
01/7/15 - kr9.75
52 Week Low
07/14/14 - kr2.37
Market Cap
537.1M
Average Volume 10 Days
660.0K
EPS TTM
kr-0.17
Shares Outstanding
98.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KANCERA AB (KAN)

Related News

No related news articles were found.

kancera ab (KAN) Related Businessweek News

No Related Businessweek News Found

kancera ab (KAN) Details

Kancera AB, a biotechnology company, engages in the development and sale of drug candidates that cure or stop the progression of cancer. The company develops drugs for the treatment of leukemia and solid tumors, based on blocking survival signals in the cancer cell and on addressing cancer metabolism. Its pharmaceutical development projects include ROR inhibitors, which are drug candidate for treatment of leukemia and solid tumors; and PFKFB inhibitors for reducing cancer’s energy supply, as well as epigenetic pharmaceutical development targeting cancer and parasitic diseases. The company was founded in 2010 and is based in Solna, Sweden.

Founded in 2010

kancera ab (KAN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kancera ab (KAN) Key Developments

Kancera AB Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Kancera AB reported consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company’s net sales were SEK 50,000 against SEK 1,354,000 a year ago. Operating loss was SEK 4,174,000 against SEK 2,083,000 a year ago. Net loss was SEK 4,141,000 or SEK 0.04 per diluted share against SEK 2,096,000 or SEK 0.05 per diluted share a year ago. Cash flow used in operating activities was SEK 4,520,000 against cash flow from operations was SEK 363,000 a year ago. Investment in tangible assets was SEK 24,000. For the year, the company’s net sales were SEK 470,000 against SEK 1,813,000 a year ago. Operating loss was SEK 15,190,000 against SEK 10,404,000 a year ago. Net loss was SEK 15,074,000 or SEK 0.17 per diluted share against SEK 7,418,000 or SEK 0.22 per diluted share a year ago. Cash flow used in operating activities was SEK 18,853,000 against SEK 6,638,000 a year ago. Investment in tangible assets was SEK 601,000 against SEK 2,000,000 a year ago.

Kancera AB Presents at BIO-Europe Spring 2015, Mar-10-2015 09:15 AM

Kancera AB Presents at BIO-Europe Spring 2015, Mar-10-2015 09:15 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Kancera AB to Report Fiscal Year 2014 Results on Feb 20, 2015

Kancera AB announced that they will report fiscal year 2014 results on Feb 20, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KAN:SS kr5.45 SEK +0.10

KAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KAN.
View Industry Companies
 

Industry Analysis

KAN

Industry Average

Valuation KAN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,093.7x
Price/Book 17.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 989.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KANCERA AB, please visit www.kancera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.